Contact Information: Contact: Ralph Barry Chief Business Officer Aegis Therapeutics LLC 1-858-618-1400 Ext. 102 Email:
Aegis Therapeutics to Present at the "13th Annual Drug Delivery Summit" in New Brunswick, NJ, September 22-23, 2008
| Source: Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwire - August 21, 2008) - Aegis Therapeutics, a drug delivery
technology licensing company and leader in transmucosal drug delivery, will
present a talk entitled: "New Technologies Expanding Practical Clinical
Uses of Peptides, Proteins, and Other Macromolecular Therapeutics" at
Insight's "13th Annual Drug Delivery Summit." The conference will be held
on September 22-23, 2008 at the Hyatt Regency, New Brunswick, NJ. Dr.
Edward T. Maggio, President and CEO of Aegis, will present studies on the
application of Aegis' Intravail® non-invasive drug delivery technology,
and Aegis' ProTek® protein stabilization technology to specific peptide,
protein, and small molecule therapeutics.
Information about the conference may be obtained from the following
website: http://www.insightinfo.com/index.cfm?ci_id=25551&la_id=1.
About Aegis Therapeutics
Aegis Therapeutics LLC is a drug delivery technology company
commercializing its patented or proprietary drug delivery and drug
formulation technologies through product-specific licenses. Our
Intravail® drug delivery technology enables the non-invasive delivery of
a broad range of protein, peptide and non-peptide macromolecular
therapeutics that can currently only be administered by injection. Aegis'
Intravail® absorption enhancement agents provide exceptionally high and
unmatched bioavailability performance, comparable in efficiency to
subcutaneous injection, via the intranasal administration route.
Intravail® has also been successfully applied to buccal, oral, and rectal
administration of both small molecule and peptidic drugs. Our ProTek®
technology allows creation of proprietary, easily manufacturable, and
stable aqueous or lyophilized dosage forms that maintain the integrity and
physiological activity of many protein and peptide therapeutics. ProTek®
technology is applicable to injectable, intranasal, and other dosage forms
of peptide or protein therapeutics.
For more information about Aegis, please visit the Aegis website
at: http://www.aegisthera.com.